CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Senhwa Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Senhwa Biosciences Inc
9F., No. 205-1
Sec. 3, Peihsin Rd
Phone: +886 289119856p:+886 289119856 NEW TAIPEI, 231  Taiwan Ticker: 64926492
Business Summary
Senhwa Biosciences, Inc. is a Taiwan-based company principally engaged in the research and development of anti-cancer new drugs and special drug substances. The Company's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The Company has not generated any revenues yet.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Benny T.Hu 75 11/1/2012 11/1/2012
Chief Financial Officer, Executive Deputy General Manager, Head of Finance & Administration, Corpor SarahChang 8/9/2024 2/27/2014
Acting Chief Operating Officer XiaohuiLuo 3/30/2023 3/30/2023
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 16 (As of 6/30/2014)
Outstanding Shares: 89,186,000 (As of 9/30/2024)
Shareholders: 26,976
Stock Exchange: TPO
Fax Number: +886 289119956


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024